China's Yingruidi raises tens of millions for eye-area RF device
What's the deal? YingruidiDealroom has a profile for this one. Try Dealroom → has raised an early-stage round of tens of millions of yuan, led by Nuerli Capital, with Tanzhen CapitalDealroom has a profile for this one. Try Dealroom → serving as sole financial adviser. The medical-aesthetics startup will use the money to market its BeaShape radiofrequency treatment device and fund its product pipeline.
What's the endgame? BeaShape targets the eye area, where thin skin and dense nerves make treatment hard and imports have long dominated. In June 2026, the device won a Class III registration from the National Medical Products Administration — the first domestic clearance for eye-area anti-ageing in the light-sound-electric category.
Why now? Radiofrequency devices are being folded into China's strict Class III regime, a shift that rewards firms holding early approvals. Founded five years ago, Yingruidi is pushing into commercialisation as that window opens.
What could go wrong? The raise is small for a capital-heavy sector where clinical trials, academic promotion, and distribution all burn cash. Yingruidi is spending across four cities — a plant in Zaozhuang, a new factory in Suzhou, a hospital-facing unit in Ningbo, and a PDRN biomaterials arm in Taicang — stretching those funds thin.
The company has disclosed no operating data since its founding: no revenue, margins, or installed base. For outsiders, that leaves its performance a black box.
One device, one bet: Almost all of Yingruidi's commercial hopes ride on BeaShape. Its supporting trial enrolled 60 subjects in a single-arm design with no control group, and the pain-score data the company touts had not been published in a peer-reviewed journal at the time of the announcement.
Founder Liu Haijing holds about 95% of the company, with Wu Qi holding 5%. The concentration speeds decisions but leaves little internal check — and raises questions about how future dilution, a board, and team incentives will be handled.
The signal: Yingruidi shows both the promise and the strain of China's domestic aesthetics-device push: a founder who secured a first-in-category clearance against entrenched imports, racing to build a business before the approval advantage fades. With rivals such as Peninsula Medical queuing for their own certificates, the contest will soon turn on price, channels, and proof — areas where a device maker still building its playbook has much to show.
Read more: sohu.com
Image credit: Generated with Gemini
